Xiaodi Qin

Xiaodi Qin

Auto-generated profile, based on publicly available information

Xiaodi Qin

Duke Cancer Institute, Duke University School of Medicine, Durham, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
RSRachid Safi
Rachid Safi
SWSuzanne E. Wardell
Suzanne E. Wardell
PWPaige Watkinson
Paige Watkinson
XQXiaodi Qin
Xiaodi Qin
MLMarissa Lee
Marissa Lee
DMDonald P McDonnell
Donald P McDonnell
Most prostate cancers express the androgen receptor (AR), and tumor growth and progression are facilitated by exceptionally low levels of systemic or intratumorally produced androgens. Thus, absolute inhibition of the androgen signaling axis remains the goal of current therapeutic approaches to treat prostate cancer (PCa). Paradoxically, high dose androgens also exhibit considerable efficacy as a treatment modality in patients with late-stage metastatic PCa. Here we show that low levels of androgens, functioning through an AR monomer, facilitate a non-genomic activation of the mTOR signaling pathway to drive proliferation. Conversely, high dose androgens facilitate the formation of AR dimers/oligomers to suppress c-MYC expression, inhibit proliferation and drive a transcriptional program associated with a differentiated phenotype. These findings highlight the inherent liabilities in current approaches used to inhibit AR action in PCa and are instructive as to strategies that can be used to develop new therapeutics for this disease and other androgenopathies.

1 November 2021 in Gynecologic Oncology
Verified
Journal Article
Closed access
LCLauren Patterson Cobb
Lauren Patterson Cobb
SSSharareh Siamakpour-Reihani
Sharareh Siamakpour-Reihani
DZDadong Zhang
Dadong Zhang
XQXiaodi Qin
Xiaodi Qin
KOKouros Owzar
Kouros Owzar
ASAngeles Alvarez Secord
Angeles Alvarez Secord

18 March 2025 in Cancer Research
Verified
Journal Article
Open access
XQXiaodi Qin
Xiaodi Qin
SSSiri H. Strand
Siri H. Strand
MLMarissa R. Lee
Marissa R. Lee
ASAashrith Saraswathibhatla
Aashrith Saraswathibhatla
DIDavid G.P. van Ijzendoorn
David G.P. van Ijzendoorn
RWRobert B. West
Robert B. West
Ductal carcinoma in situ (DCIS) is a risk factor for subsequent invasive breast cancer (IBC). To identify events in DCIS that lead to invasive cancer, we performed single-cell RNA sequencing on DCIS lesions and matched normal breast tissue. Inferred copy-number variation was used to identify neoplastic epithelial cells from clinical specimens, which contained a mixture of DCIS and normal ducts. Phylogenetic analysis demonstrated intratumoral clonal heterogeneity that was associated with significant gene expression differences. Classification of epithelial cells into mammary cell states revealed that subclones contained a mixture of cell states, suggesting an ongoing pattern of differentiation after neoplastic transformation. Cell state proportions were significantly different based on estrogen receptor expression, with estrogen receptor–negative DCIS more closely resembling the distribution in the normal breast, particularly with respect to cells with basal characteristics. Specific alterations in cell state proportions were associated with progression to invasive cancer in a cohort of DCIS with longitudinal outcome. Ongoing transcription of key basement membrane (BM) genes occurred in specific subsets of epithelial cell states, including basal/myoepithelial, which are diminished in DCIS. In the transition to IBC, the BM protein laminin, but not COL4, was altered in DCIS adjacent to invasion. Loss of COL4, but not laminin, in an in vitro DCIS model led to an invasive phenotype. These findings suggest that the process of invasion is a loss-of-function event due to an imbalance in critical cell populations essential for BM integrity rather than a gain of an invasive phenotype by neoplastic cells. Significance: Single-cell analyses reveal ductal carcinoma in situ comprises multiple genetic clones with significant phenotypic diversity and link alterations in epithelial cell states and basement membrane integrity with invasive breast cancer progression.

13 October 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
BPBrendon M. Patierno
Brendon M. Patierno
WFWen-Chi Foo
Wen-Chi Foo
TATyler Allen
Tyler Allen
JSJason A. Somarelli
Jason A. Somarelli
KWKathryn E. Ware
Kathryn E. Ware
JFJennifer A. Freedman
Jennifer A. Freedman

24 June 2026 in Research Square
Verified
Preprint
Open access
PDF file
EOEziafa Oduah
Eziafa Oduah
JGJhanelle Gray
Jhanelle Gray
TSThomas Stinchcombe
Thomas Stinchcombe
SWSteven Wolf
Steven Wolf
XQXiaodi Qin
Xiaodi Qin
SAScott Antonia
Scott Antonia
In preclinical models, PCSK9 mediates cancer immunotherapy resistance and may serve as a novel immuno-inhibitory target. Herein, we report the results from a multi-center, single arm, phase II study evaluating the clinical activity and safety of the PCSK9 inhibitor alirocumab, in combination with the anti-PD1 antibody cemiplimab, in non-small cell lung cancer (NSCLC) patients with disease progression after previous immune checkpoint blockade. The primary endpoint was objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), duration of response (DOR), disease control rate (DCR) and safety, and an exploratory objective was to analyze potential biomarkers of response. Sixty patients were enrolled, and 58 were evaluable for ORR. The ORR was 14.78% (90% CI, 5.30, 25.43), the median PFS was 2.5 months (95% CI, 1.5-3), and the median OS was 7.3 months (95% CI, 5.4 – 12.3). The most common treatment related adverse events (all grades) were anemia and fatigue. Grade 3 adverse events occurred in seven (12%) patients and were anemia, Guillain-Barre Syndrome and elevated amino transferase. There were no treated related adverse events of grade 4 or greater in the study population. Biomarker analysis identified superior outcomes in NSCLC harboring PIK3CA, PTEN, or AKT1 alterations. The ORR in patients with PIK3CA, PTEN, or AKT1 alterations (n=17) was 29.4% (95% CI, 10.3% - 56.0%). No objective responses were observed in the absence of PIK3CA, PTEN or AKT1 alterations (n=39). The presence of PIK3CA, PTEN or AKT1 alterations was significantly associated with response, p 0.0032 (two-sided, Fisher’s exact test). Further translational studies revealed the impact of PIK3CA, PTEN or AKT1 alterations on intratumoral PCSK9, providing a biological rationale for the pattern of response and clinical benefit. These findings provide clinical proof-of-principle that PCSK9 inhibition can overcome immunotherapy resistance in a subset of patients and suggest that PIK3CA/PTEN/AKT1 pathway plays a significant role in PCSK9 mediated immune evasion and could be a biomarker of response. These findings warrant further investigation in larger confirmatory studies.